Cardiovascular risk reduction and preservation of renal function in the early nephropathy patient

Advances in Chronic Kidney Disease
Peter A McCullough

Abstract

The obesity pandemic is driving secondary epidemics of type II diabetes and hypertension, resulting in rising rates of patients with early nephropathy at risk for cardiovascular disease. Estimation of glomerular filtration rate and assessment of microalbuminuria are key screening measures for this patient population. Combined with reduction of traditional cardiovascular risk factors, reducing the rate of progression of chronic kidney disease is expected to have an additive beneficial effect in this population. This article reviews a common strategy for prevention of both cardiac and kidney endpoints in patients with early nephropathy.

References

Feb 18, 1997·Circulation·G M ChertowJ Daley
Dec 5, 1998·Annals of Internal Medicine·P KrijnenJ D Habbema
Apr 23, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W F Keane, G Eknoyan
Jul 21, 1999·Kidney International. Supplement·H Oda, W F Keane
Aug 19, 1999·The New England Journal of Medicine·R W Schrier, W T Abraham
Sep 15, 2000·Journal of the American College of Cardiology·P A McCulloughS Borzak
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
May 31, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R A FaticaE W Young
May 31, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J N BeattieP A McCullough
Jun 21, 2001·JAMA : the Journal of the American Medical Association·L Y AgodoaUNKNOWN African American Study of Kidney Disease and Hypertension (AASK) Study Group
Jun 28, 2001·Archives of Internal Medicine·R Toto
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Dec 18, 2001·Medicinal Research Reviews·Michele BuemiNicola Frisina
Jan 5, 2002·The New England Journal of Medicine·K T Weber
May 16, 2002·Circulation·L A SzczechUNKNOWN Bypass Angioplasty Revascularization Investigation (BARI) Investigators
Jun 5, 2003·Annals of Internal Medicine·Michael G Shlipak
Jul 16, 2003·Archives of Internal Medicine·George L BakrisUNKNOWN RENAAL Study Group
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,

❮ Previous
Next ❯

Citations

Feb 19, 2005·Advances in Chronic Kidney Disease·Kathryn J Wiggins, David W Johnson
Mar 5, 2009·Bioinspiration & Biomimetics·C LaschiP Dario
Apr 9, 2014·The Journal of Clinical Hypertension·Dimitris P PapadopoulosVasilios Papademetriou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
S F LeaveyE W Young
Annals of Internal Medicine
J R WeisingerR S Swenson
The New England Journal of Medicine
J E MansonF E Speizer
JAMA : the Journal of the American Medical Association
J E MansonW C Willett
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
Y SasatomiS Takebayashi
© 2022 Meta ULC. All rights reserved